Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).

Trial Details

NCT ID
NCT06796998
Phase
PHASE2
Sponsor
Izidore Lossos, MD
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Epcoritamab
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Men and women aged 18 years or older at the time of signing informed consent.
  • Able and willing to sign the informed consent form (ICF).
  • Ability to comply with the trial protocol.
  • Histologically confirmed Marginal Zone Lymphoma (MZL) of Extranodal Marginal Zone Lymphoma (EMZL), Nodal Marginal Zone Lymphoma (NMZL) and Splenic …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →